title: Rearrangement of energetic and substrate utilization networks compensate for chronic myocardial creatine kinase deficiency.
abstract: Plasticity of the cellular bioenergetic system is fundamental to every organ function, stress adaptation and disease tolerance. Here, remodelling of phosphotransfer and substrate utilization networks in response to chronic creatine kinase (CK) deficiency, a hallmark of cardiovascular disease, has been revealed in transgenic mouse models lacking either cytosolic M-CK (M-CK(-/-)) or both M-CK and sarcomeric mitochondrial CK (M-CK/ScCKmit(-/-)) isoforms. The dynamic metabolomic signatures of these adaptations have also been defined. Tracking perturbations in metabolic dynamics with (18)O and (13)C isotopes and (31)P NMR and mass spectrometry demonstrate that hearts lacking M-CK have lower phosphocreatine (PCr) turnover but increased glucose-6-phosphate (G-6-P) turnover, glucose utilization and inorganic phosphate compartmentation with normal ATP γ-phosphoryl dynamics. Hearts lacking both M-CK and sarcomeric mitochondrial CK have diminished PCr turnover, total phosphotransfer capacity and intracellular energetic communication but increased dynamics of β-phosphoryls of ADP/ATP, G-6-P and γ-/β-phosphoryls of GTP, indicating redistribution of flux through adenylate kinase (AK), glycolytic and guanine nucleotide phosphotransfer circuits. Higher glycolytic and mitochondrial capacities and increased glucose tolerance contributed to metabolic resilience of M-CK/ScCKmit(-/-) mice. Multivariate analysis revealed unique metabolomic signatures for M-CK(-/-) and M-CK/ScCKmit(-/-) hearts suggesting that rearrangements in phosphotransfer and substrate utilization networks provide compensation for genetic CK deficiency. This new information highlights the significance of integrated CK-, AK-, guanine nucleotide- and glycolytic enzyme-catalysed phosphotransfer networks in supporting the adaptivity and robustness of the cellular energetic system.
authors: Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. dzeja.petras@mayo.edu
authors: Petras P
authors: PP
authors: Dzeja
authors: Kirsten
authors: K
authors: Hoyer
authors: Rong
authors: R
authors: Tian
authors: Song
authors: S
authors: Zhang
authors: Emirhan
authors: E
authors: Nemutlu
authors: Matthias
authors: M
authors: Spindler
authors: Joanne S
authors: JS
authors: Ingwall
mesh_terms: D000263:Adenylate Kinase / Q000378:metabolism; D000818:Animals; D052279:Creatine Kinase, MB Form / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D052281:Creatine Kinase, Mitochondrial Form / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D005951:Glucose Tolerance Test; D006019:Glycolysis; D006150:Guanine Nucleotides / Q000378:metabolism; D055432:Metabolomics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008929:Mitochondria, Heart / Q000378:metabolism; D018482:Muscle, Skeletal / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*
chemical_list: D006150:Guanine Nucleotides; D052279:Creatine Kinase, MB Form; D052281:Creatine Kinase, Mitochondrial Form; D000263:Adenylate Kinase; D005947:Glucose